TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway

Ilya V. Ulasov*, Olja Mijanovic, Solomiia Savchuk, Edgar Gonzalez-Buendia, Adam Sonabend, Ting Xiao, Petr Timashev, Maciej S. Lesniak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Glioblastoma (GBM) is one of the most aggressive primary brain tumors with frequent recurrences following the standard methods of treatment—temozolomide (TMZ), ionizing radiation and surgical resection. The objective of our study was to investigate GBM resistance mediated via MMP14 (matrix metalloproteinase 14). We used multiple PDX GBM models and established glioma cell lines to characterize expression and subcellular localization of MMP14 after TMZ treatment. We performed a Kiloplex ELISA-based array to evaluate changes in cellular proteins induced by MMP14 expression and translocation. Lastly, we conducted functional and mechanistic studies to elucidate the role of DLL4 (delta-like canonical notch ligand 4) in regulation of glioma stemness, particularly in the context of its relationship to MMP14. We detected that TMZ treatment promotes nuclear translocation of MMP14 followed by extracellular release of DLL4. DLL4 in turn stimulates cleavage of Notch3, its nuclear translocation and induction of sphering capacity and stemness.

Original languageEnglish (US)
Pages (from-to)2218-2228
Number of pages11
JournalInternational Journal of Cancer
Issue number8
StatePublished - Apr 15 2020


  • glioblastoma
  • stemness
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway'. Together they form a unique fingerprint.

Cite this